Long-term Rescue of a Lethal Inherited Disease by Adeno-associated Virus-mediated Gene Transfer in a Mouse Model of Molybdenum-cofactor Deficiency

Overview

Journal Am J Hum Genet

Publisher Cell Press

Specialty Genetics

Date 2007 Jan 20

PMID 17236133

Citations 29

Authors

S Kugler

R Hahnewald

M Garrido

J Reiss

Affiliations

Soon will be listed here.

Abstract

Molybdenum cofactor (MoCo) deficiency is a progressive neurological disorder that inevitably leads to early childhood death because of the lack of any effective therapy. In a mouse model of MoCo deficiency type A, the most frequent form of this autosomal recessively inherited disease, the affected animals show the biochemical characteristics of sulphite and xanthine intoxication and do not survive >2 wk after birth. We have constructed a recombinant-expression cassette for the gene MOCS1, which, via alternative splicing, facilitates the expression of the proteins MOCS1A and MOCS1B, both of which are necessary for the formation of a first intermediate, cyclic pyranopterin monophosphate (cPMP), within the biosynthetic pathway leading to active MoCo. A recombinant adeno-associated virus (AAV) vector was used to express the artificial MOCS1 minigene, in an attempt to cure the lethal MOCS1-deficient phenotype. The vector was used to transduce Mocs1-deficient mice at both 1 and 4 d after birth or, after a pretreatment with purified cPMP, at 40 d after birth. We report here that all Mocs1-deficient animals injected with a control AAV-enhanced green fluorescent protein vector died approximately 8 d after birth or after withdrawal of cPMP supplementation, whereas AAV-MOCS1-transduced animals show significantly increased longevity. A single intrahepatic injection of AAV-MOCS1 resulted in fertile adult animals without any pathological phenotypes.

Citing Articles

Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy.

Cheng S, van Gaalen M, Bahr M, Garea-Rodriguez E, Kugler S Mol Ther Methods Clin Dev. 2021; 23:1-10.

PMID: 34552998 PMC: 8426472. DOI: 10.1016/j.omtm.2021.07.007.

Learning from the worm: the effectiveness of protein-bound Moco to treat Moco deficiency.

Sewell A, Han M Genes Dev. 2021; 35(3-4):177-179.

PMID: 33526584 PMC: 7849358. DOI: 10.1101/gad.348176.120.

Systemic AAV6-synapsin-GFP administration results in lower liver biodistribution, compared to AAV1&2 and AAV9, with neuronal expression following ultrasound-mediated brain delivery.

Weber-Adrian D, Kofoed R, Silburt J, Noroozian Z, Shah K, Burgess A Sci Rep. 2021; 11(1):1934.

PMID: 33479314 PMC: 7820310. DOI: 10.1038/s41598-021-81046-5.

Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency.

Misko A, Liang Y, Kohl J, Eichler F Neurol Genet. 2020; 6(4):e486.

PMID: 32802950 PMC: 7371372. DOI: 10.1212/NXG.0000000000000486.

Alternative splicing of the bicistronic gene molybdenum cofactor synthesis 1 () uncovers a novel mitochondrial protein maturation mechanism.

Mayr S, Roper J, Schwarz G J Biol Chem. 2020; 295(10):3029-3039.

PMID: 31996372 PMC: 7062190. DOI: 10.1074/jbc.RA119.010720.

References

Malik J, Shevtsova Z, Bahr M, Kugler S . Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther. 2005; 11(3):373-81. DOI: 10.1016/j.ymthe.2004.11.014. View

Shevtsova Z, Malik J, Michel U, Bahr M, Kugler S . Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol. 2004; 90(1):53-9. DOI: 10.1113/expphysiol.2004.028159. View

Shimo T, Ashizawa N, Matsumoto K, Nakazawa T, Nagata O . Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats. Toxicol Sci. 2005; 87(1):267-76. DOI: 10.1093/toxsci/kfi210. View

Schwarz G . Molybdenum cofactor biosynthesis and deficiency. Cell Mol Life Sci. 2005; 62(23):2792-810. PMC: 11145942. DOI: 10.1007/s00018-005-5269-y. View

Manno C, Pierce G, Arruda V, Glader B, Ragni M, Rasko J . Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006; 12(3):342-7. DOI: 10.1038/nm1358. View

Nathwani A, Gray J, Ng C, Zhou J, Spence Y, Waddington S . Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2005; 107(7):2653-61. PMC: 1895379. DOI: 10.1182/blood-2005-10-4035. View

Nienhuis A, Dunbar C, Sorrentino B . Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006; 13(6):1031-49. DOI: 10.1016/j.ymthe.2006.03.001. View

Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Tuneyoshi K, Matsui K . Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II. Metabolism. 2003; 52(11):1501-4. DOI: 10.1016/s0026-0495(03)00272-5. View

Ichida K, Matsumura T, Sakuma R, Hosoya T, Nishino T . Mutation of human molybdenum cofactor sulfurase gene is responsible for classical xanthinuria type II. Biochem Biophys Res Commun. 2001; 282(5):1194-200. DOI: 10.1006/bbrc.2001.4719. View

10.

Reiss J . The bicistronic MOCS1 gene has alternative start codons on two mutually exclusive exons. Mol Genet Metab. 2002; 76(4):340-3. DOI: 10.1016/s1096-7192(02)00100-2. View

11.

Lee H, Adham I, Schwarz G, Kneussel M, Sass J, Engel W . Molybdenum cofactor-deficient mice resemble the phenotype of human patients. Hum Mol Genet. 2002; 11(26):3309-17. DOI: 10.1093/hmg/11.26.3309. View

12.

Vorbach C, Scriven A, Capecchi M . The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev. 2002; 16(24):3223-35. PMC: 187506. DOI: 10.1101/gad.1032702. View

13.

Hauck B, Chen L, Xiao W . Generation and characterization of chimeric recombinant AAV vectors. Mol Ther. 2003; 7(3):419-25. PMC: 2636682. DOI: 10.1016/s1525-0016(03)00012-1. View

14.

Manno C, Chew A, Hutchison S, Larson P, Herzog R, Arruda V . AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003; 101(8):2963-72. DOI: 10.1182/blood-2002-10-3296. View

15.

Reiss J, Johnson J . Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH. Hum Mutat. 2003; 21(6):569-76. DOI: 10.1002/humu.10223. View

16.

Tenenbaum L, Lehtonen E, Monahan P . Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003; 3(6):545-65. DOI: 10.2174/1566523034578131. View

17.

Couto L, Parker A, Gordon J . Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction. Hum Gene Ther. 2004; 15(3):287-91. DOI: 10.1089/104303404322886138. View

18.

Schwarz G, Angel Santamaria-Araujo J, Wolf S, Lee H, Adham I, Grone H . Rescue of lethal molybdenum cofactor deficiency by a biosynthetic precursor from Escherichia coli. Hum Mol Genet. 2004; 13(12):1249-55. DOI: 10.1093/hmg/ddh136. View

19.

Johnson J, Wuebbens M, Mandell R, Shih V . Molybdenum cofactor biosynthesis in humans. Identification of two complementation groups of cofactor-deficient patients and preliminary characterization of a diffusible molybdopterin precursor. J Clin Invest. 1989; 83(3):897-903. PMC: 303764. DOI: 10.1172/JCI113974. View

20.

Johnson J, Rajagopalan K, WADMAN S . Human molybdenum cofactor deficiency. Adv Exp Med Biol. 1993; 338:373-8. DOI: 10.1007/978-1-4615-2960-6_77. View